Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
0.630
+0.004 (0.71%)
Nov 21, 2024, 11:54 AM EST - Market open
Quoin Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Selling, General & Admin | 5.98 | 6.07 | 6.58 | 4.5 | 1.43 | 1.51 |
Research & Development | 3.36 | 3.31 | 2.67 | 1.56 | 0.24 | 0.05 |
Operating Expenses | 9.34 | 9.38 | 9.26 | 6.06 | 1.67 | 1.56 |
Operating Income | -9.34 | -9.38 | -9.26 | -6.06 | -1.67 | -1.56 |
Interest Expense | - | - | -0.71 | -1.37 | -0.05 | - |
Interest & Investment Income | 0.69 | 0.69 | 0.1 | - | - | - |
Other Non Operating Income (Expenses) | -0.05 | -0 | 0.08 | -12.78 | - | - |
EBT Excluding Unusual Items | -8.7 | -8.69 | -9.8 | -20.21 | -1.72 | -1.56 |
Other Unusual Items | - | - | 0.42 | -1.25 | -0.38 | - |
Pretax Income | -8.7 | -8.69 | -9.38 | -21.46 | -2.1 | -1.56 |
Net Income | -8.7 | -8.69 | -9.38 | -21.46 | -2.1 | -1.56 |
Preferred Dividends & Other Adjustments | - | - | 0.07 | - | - | - |
Net Income to Common | -8.7 | -8.69 | -9.45 | -21.46 | -2.1 | -1.56 |
Shares Outstanding (Basic) | 3 | 1 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 3 | 1 | 0 | 0 | 0 | 0 |
Shares Change (YoY) | 336.80% | 346.38% | 666.91% | 31.43% | - | - |
EPS (Basic) | -2.64 | -9.64 | -46.80 | -815.39 | -104.62 | -77.91 |
EPS (Diluted) | -2.64 | -9.64 | -46.80 | -815.39 | -104.62 | -77.91 |
Free Cash Flow | -8.84 | -7.86 | -8.48 | -5.72 | -1.34 | -1.3 |
Free Cash Flow Per Share | -2.68 | -8.73 | -42.01 | -217.31 | -66.84 | -64.85 |
EBITDA | -9.24 | -9.27 | -9.15 | -5.96 | -1.57 | -1.54 |
D&A For EBITDA | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.02 |
EBIT | -9.34 | -9.38 | -9.26 | -6.06 | -1.67 | -1.56 |
Source: S&P Capital IQ. Standard template.
Financial Sources.